Q-1801 / Viva Biotech - LARVOL DELTA

QureBio raises CNY 100 M in series C1 for accelerating core pipelines (Biospectrumasia) - "China-based startup Qure Biotechnology (Shanghai) has completed a Series C1 financing round. The financing raised nearly CNY 100 million (approximately $14 million) and was led exclusively by Efung Capital. This infusion of capital will be used to accelerate QureBio's clinical trials and advance its pipeline of novel antibody therapeutics....Key pipeline developments include: Q-1802 (Claudin18.2/PD-L1 bispecific antibody)...Q-1801 (SIRPα/PD-L1 bispecific antibody)...PD-1 Antibody-Cytokine Fusion Candidate."

Financing • Gastric Cancer • Pancreatic Cancer